Spectranetics Receives CE for Drug-Coated Balloon

The Spectranetics Corporation announced that its Stellarex™ 0.014” Drug-coated Angioplasty Balloon (DCB) has received the CE mark. The Stellarex 0.014” device is designed to treat small vessels, below-the-knee disease, and challenging critical limb ischemia (CLI) in patients.  The combination of the currently available Stellarex 0.035” and the new 0.014” line … Continue reading

Share